Research programme: gastrointestinal disease therapeutics - Altos Therapeutics

Drug Profile

Research programme: gastrointestinal disease therapeutics - Altos Therapeutics

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altos Therapeutics
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 01 Jul 2016 Altos Therapeutics enters into a definitive agreement with Takeda that includes an exclusive option for Takeda to acquire Altos
  • 09 Jan 2015 Altos Therapeutics receives patent allowance for its D2/D3 drug candidates in Mexico
  • 12 Feb 2014 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top